Elisigen

Seoul, South Korea · Founded 2018 · Privately Held (backing)

Developer of an adeno-associated virus (AAV) gene therapy designed to improve the quality of life of patients. Elisigen is based in Seoul, South Korea and was founded in 2018. Its last reported valuation was $74.5 million in Jul 2021. It has raised $83.7 million.

Last reported valuation
$74.5M
Oct 2026
Priced at
—
Total raised
$83.7M
Last round
—

Who backs Elisigen?

24 investors
InvestorType
KB InvestmentVenture capital
Korea Investment PartnersVenture capital
Korea Development BankOther
Partners InvestmentVenture capital
Premier PartnersPE / buyout
DAYLI PartnersVenture capital
NH Investment & SecuritiesOther
Yuanta InvestmentVenture capital
Ulmus InvestmentVenture capital
IBK CapitalOther
+ 14 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Elisigen investors

24 investors are on record for Elisigen, including KB Investment, Korea Investment Partners, Korea Development Bank and Partners Investment. By type, the record holds 6 venture capital firms and 1 private equity firm.

Free account
More of Elisigen with a free account
  • ·The complete investor list: 24 names
  • ·Watch Elisigen: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 24 firms already write checks for companies like Elisigen. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View